Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Man Li
Institution:
Second Hospital of Tianjin Medical University
Observed institution:
Second Hospital of Tianjin Medical University
ORCID:
0000-0001-7222-3527
Observed ORCID:
0000-0001-7222-3527
OpenAlex ID:
A5042356458
Rapamycin Attenuates Anxiety and Depressive Behavior Induced by Helicobacter pylori in Association with Reduced Circulating Levels of Ghrelin
2022
·
Jiageng Tian
, Zeyu Wang
, et al.
·
Neural Plasticity
·
19
PDF
Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
·
Clinical Cancer Research
·
12
PDF
Association of Helicobacter pylori Infection with Depression and Anxiety: A Systematic Review and Meta‐Analysis
2024
·
Lu Li
, Yadi Ren
, et al.
·
International Journal of Clinical Practice
·
6
PDF
Exploration of a new method for Photoshop-assisted endoscopic ultrasound to distinguish gastrointestinal stromal tumor and leiomyoma
2022
·
Ying Zhao
, Zeyu Wang
, et al.
·
Scandinavian Journal of Gastroenterology
·
6
A Lightweight Machine Learning Model for High Precision Gastrointestinal Stromal Tumors Identification
2025
·
Xin Sun
, Xiwen Mo
, et al.
·
Bioengineering
·
3
PDF
Data from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Table S1 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Supplementary Table S5 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Supplementary Table S2 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Supplementary Table S3 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Figure S1 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Table S4 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Figure S2 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Show more works
View as search
Works count:
13
Citation count:
46
H-index:
4
I10-index:
2
Year
Topic
Type